Abstract

To assess removal of cytomegalovirus (CMV) by leukocyte depletion (LD) filters, we developed a spiking model of latent virus using peripheral blood mononuclear cells (PBMCs) infected by coculture with CMV-infected human fibroblasts. Infected PBMCs were purified by dual magnetic column selection and then spiked into whole blood units or buffy coat pools prior to LD by filtration. CMV load and fibroblast contamination were assessed using quantitative CMV DNA real-time PCR and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) of mRNA encoding the fibroblast-specific splice variant of prolyl-4-hydroxylase, respectively. After correcting for fibroblast-associated CMV, the mean CMV load was reduced in whole blood by LD from 7.42 × 102 to 1.13 copies per microliter (2.8110log reduction) and from 3.8 × 102 to 4.77 copies per microliter (1.910log reduction) in platelets. These results suggest that LD by filtration reduces viral burden but does not completely remove CMV from blood components. (Blood. 2004;103:1137-1139)

Introduction

Primary cytomegalovirus (CMV) infection results in life-long carriage of latent virus, notably in CD14+ monocytes.1  Reactivation of donor CMV following transfusion2  is avoided by selecting CMV-seronegative donors for vulnerable patients. Because universal leukocyte depletion (LD) has been widely implemented, it is debated whether LD alone could provide equivalent protection.3,4  Eight studies have shown no transmissions following prestorage LD,5,6  but a recent study reports increased transmission from LD CMV-seropositive components.7 

Quantitative real-time polymerase chain reaction (PCR) has the dynamic range to assess CMV removal by LD,8,9  but due to low copy number, we and others9  have failed to detect viremia in seropositive donors, and even optimal CMV PCR would require virtually all leukocytes in an LD component (less than 106).10  We found techniques reported to increase CMV copy number (pollen,11  γ-interferon, hydrocortisone, granulocyte-macrophage colony-stimulating factor [GM-CSF], and allogeneic cells2 ) to be insufficiently robust for assessment of LD. We have previously used infected T lymphocytes and real-time PCR to assess human T-cell leukemia virus-I (HTLV-I) removal by LD.12  A CMV-infected T-cell line has also been described to measure CMV removal,13  but T cells are not a major physiological reservoir of CMV. We have therefore modified a previously described system14  to generate CMV-infected mononuclear cells, including CD14+ monocytes, for spiking into blood donations prior to LD.

Study design

With ethics committee approval and donor consent, 450-mL blood donations from 6 CMV-seronegative donors were collected into citrate phosphate dextrose. Peripheral blood mononuclear cells (PBMCs) were prepared from a 24 mL aliquot by density gradient separation (mean yield, 1.52 × 107 ± 0.27 × 107) and cultured for 12 hours with 2 × 106 human embryonic fibroblasts infected with human CMV strain AD169. PBMCs were separated from fibroblasts by double selection using magnetic beads coated with antihuman fibroblast antibodies and then anti-CD45. Leukocyte subset distribution in a representative sample of recovered PBMCs was analyzed by dual-label flow cytometry using murine phycoerythrin (PE) anti-CD45 plus fluorescein isothiocyanate (FITC) anti-CD3, or FITC CD19, or FITC anti-CD14.

Following overnight hold at 4°C, each whole blood unit was spiked with its own CMV-infected PBMCs and LD was undertaken using Pall WBF3 filters (Pall Europe, Portsmouth, United Kingdom), which were then backwashed with 60 mL saline. A similar approach was used with pooled platelet concentrates (Pall AutoStop filters; Pall Europe), except that PBMCs were prepared from pools of 4 CMV-seronegative buffy coats, with a mean yield of 4.52 × 107 ± 2.42 × 107 cells. Leukocyte counting (sensitivity, 1 leukocyte per microliter) was performed by flow cytometry (LeucoCOUNT, Becton Dickinson, Franklin Lakes, NJ).

CMV quantification (sensitivity, 1 copy per microliter) was performed by amplifying nucleotides 2410 to 2481 of immediate early (IE) gene DNA using real-time TaqMan PCR (ABI Prism 7700; Applied Biosystems, Warrington, United Kingdom); forward primer 5′-CAAGAACTCAGCCTTCCCTAAGAC-3′, reverse primer 5′-TGAGGCAAGTTCTGCAATGC-3′; TaqMan probe 5′-CCAATGGCTGCAGTCAGGCCATG-3′. For fibroblast quantification, reverse-transcription real-time PCR was developed to amplify exon 12a of mRNA encoding a fibroblast-specific splice variant of prolyl-4-hydroxylase15 ; forward primer 5′-GAACCGCACTTCGACTTCTCTAG-3′, reverse primer 5′-CTCTCAGGTTYCGCTCGTCC-3′; TaqMan probe 5′-TGATGAGCGACCTTTTGACAGCGG-3′.

The size and sequence of PCR amplicons were confirmed. CMV IE DNA and prolyl-4-hydroxylase mRNA assays were linear over 410logs. To create a standard curve for fibroblast quantification, mRNA was extracted from dilutions of fibroblasts from 1.5 × 103 to 1.5 × 10-1/mL and assayed for prolyl-4-hydroxylase. The contribution of CMV-infected fibroblasts to the overall CMV signal was calculated from a standard curve constructed by diluting CMV-infected fibroblasts from 8 × 104 to 8 × 10-1/mL in 4 × 106 CMV-negative mononuclear cells and assaying each dilution for CMV DNA. This demonstrated a mean CMV load of 3 copies per fibroblast. After fibroblast quantification, the calculated fibroblast-associated CMV signal was subtracted from the total CMV copy number to obtain the CMV load attributable to PBMCs at each stage.

Results and discussion

The mononuclear cell distribution in a single representative spiking sample was CD3, 63%; CD14, 11%; and CD19, 26%. Purification achieved mean fibroblast removal from whole blood and buffy coat-derived PBMCs of 96.3% ± 5.4% and 77.21% ± 20.2%, respectively, with corresponding CMV recoveries of 2.67% ± 1.87% and 13.9% ± 10.9%. The CMV signal attributable to fibroblasts in the whole blood spike was less than 1% in 5 samples and 16% in the sixth, the corresponding figures for the platelet spike being less than 11% in 5 samples and 37.7% in the sixth (Table 1).

Table 1.

CMV recovery in the mononuclear cell preparation used to spike whole blood units (n = 6) and platelet units (n = 6)


CMV copies

A

B

C

D

E

F

Mean log copy no. (SD)

Mean copy no.
Spiking samples for whole blood units         
After coculture   1.64 × 109  2.52 × 108  1.42 × 109  5.92 × 108  1.53 × 109  2.75 × 108  8.86 (0.38)   7.26 × 108 
After purification, in PBMCs for spiking   5.08 × 107  4.69 × 106  2.90 × 107  3.70 × 107  2.50 × 107  3.19 × 106  7.22 (0.50)   1.65 × 107 
% CMV recovery*  3.1   1.86   2.04   6.25   1.63   1.16   —   —  
CMV signal in final spike attributable to fibroblasts   3.3 × 105  7.5 × 105  9.9 × 103  8.1 × 103  8.1 × 102  1.2 × 104  4.38 (1.11)   2.4 × 104 
% CMV from fibroblasts†   0.65   16   0.03   0.02   0.003   0.37   —   —  
Spiking samples for platelet units         
After coculture   1.8 × 108  5.1 × 108  1.5 × 109  1.8 × 109  4.5 × 108  1.2 × 109  8.85 (0.38)   7.15 × 108 
After purification, in PBMCs for spiking   6.38 × 106  5.62 × 107  6.33 × 107  5.86 × 108  8.78 × 107  1.51 × 108  7.87 (0.72)   7.49 × 107 
% CMV recovery‡   3.54   11   4.22   32.6   19.5   12.6   —   —  
CMV signal in final spike attributable to fibroblasts   2.4 × 106  1.44 × 106  6.6 × 106  2.9 × 106  9.6 × 106  2.4 × 105  5.86 (1.13)   7.31 × 105 
% CMV from fibroblasts§
 
37.7
 
2.56
 
0.01
 
0.51
 
10.9
 
0.16
 

 

 

CMV copies

A

B

C

D

E

F

Mean log copy no. (SD)

Mean copy no.
Spiking samples for whole blood units         
After coculture   1.64 × 109  2.52 × 108  1.42 × 109  5.92 × 108  1.53 × 109  2.75 × 108  8.86 (0.38)   7.26 × 108 
After purification, in PBMCs for spiking   5.08 × 107  4.69 × 106  2.90 × 107  3.70 × 107  2.50 × 107  3.19 × 106  7.22 (0.50)   1.65 × 107 
% CMV recovery*  3.1   1.86   2.04   6.25   1.63   1.16   —   —  
CMV signal in final spike attributable to fibroblasts   3.3 × 105  7.5 × 105  9.9 × 103  8.1 × 103  8.1 × 102  1.2 × 104  4.38 (1.11)   2.4 × 104 
% CMV from fibroblasts†   0.65   16   0.03   0.02   0.003   0.37   —   —  
Spiking samples for platelet units         
After coculture   1.8 × 108  5.1 × 108  1.5 × 109  1.8 × 109  4.5 × 108  1.2 × 109  8.85 (0.38)   7.15 × 108 
After purification, in PBMCs for spiking   6.38 × 106  5.62 × 107  6.33 × 107  5.86 × 108  8.78 × 107  1.51 × 108  7.87 (0.72)   7.49 × 107 
% CMV recovery‡   3.54   11   4.22   32.6   19.5   12.6   —   —  
CMV signal in final spike attributable to fibroblasts   2.4 × 106  1.44 × 106  6.6 × 106  2.9 × 106  9.6 × 106  2.4 × 105  5.86 (1.13)   7.31 × 105 
% CMV from fibroblasts§
 
37.7
 
2.56
 
0.01
 
0.51
 
10.9
 
0.16
 

 

 

The proportion of CMV signal attributable to fibroblast contamination is also shown. A mean of 3 CMV copies per fibroblast is used in the calculation.—indicates not applicable.

Mean % (SD): *2.67 (1.87); †0.65 (1.09); ‡13.9 (10.9); §8.64 (14.8).

All LD units contained less than 5 × 106 leukocytes per unit. After correcting for CMV attributable to fibroblasts, whole blood LD reduced the CMV load from a mean of 742 to a mean of 1.13 CMV genome copies per microliter, a mean reduction of 2.81 ± 0.3110log (Table 2). For platelets, mean CMV levels before and after LD were 380 and 4.77 copies per microliter, respectively, a mean reduction of 1.9 ± 0.6410log. The mean postfiltration plasma signal from whole blood and platelets was 1.52 (range, 0.05-3.72) and 6.19 (range, 1.09-12.8) copies per microliter, respectively. Backwashing whole blood and platelet filters resulted in means of 75% and 27% CMV recovery, respectively.

Table 2.

Contaminating fibroblasts and CMV copies in whole blood and pooled platelet units before and after LD (n = 6)




A

B

C

D

E

F

Mean (SD)

Mean copy no.
Whole blood         
Fibroblasts per microliter          
Before LD   2.60   1.30   4.37   2.63   9.47   2.83   3.87 (2.91)*  —  
After LD   0.00   0.00   0.00   0.15   0.00   0.00   0.03*  —  
Corrected CMV copies per microliter          
Before LD   4060   188   420   2880   1760   103   2.87 (0.66)†   742  
After LD   3.96   0.51   1.07   3.77   0.85   0.30   0.053 (0.45)†   1.13  
Log10 CMV reduction   3.00   2.56   2.59   2.88   3.31   2.53   2.81 (0.31)‡   —  
Platelets         
Fibroblasts per microliter          
Before LD   8.2   4.4   3.3   4.2   8.1   6.1   5.72 (2.09)*  —  
After LD   0.00   0.00   0.00   0.00   0.00   0.00   0.00*  —  
Corrected CMV copies per microliter          
Before LD   88.4   631   824   1960   57.9   598   2.58 (0.59)†   380  
After LD   0.44   2.06   2.19   77.9   4.26   17.9   0.679 (0.79)†   4.77  
Log10 CMV reduction
 
2.30
 
2.49
 
2.57
 
1.40
 
1.13
 
1.52
 
1.90 (0.64)‡
 

 



A

B

C

D

E

F

Mean (SD)

Mean copy no.
Whole blood         
Fibroblasts per microliter          
Before LD   2.60   1.30   4.37   2.63   9.47   2.83   3.87 (2.91)*  —  
After LD   0.00   0.00   0.00   0.15   0.00   0.00   0.03*  —  
Corrected CMV copies per microliter          
Before LD   4060   188   420   2880   1760   103   2.87 (0.66)†   742  
After LD   3.96   0.51   1.07   3.77   0.85   0.30   0.053 (0.45)†   1.13  
Log10 CMV reduction   3.00   2.56   2.59   2.88   3.31   2.53   2.81 (0.31)‡   —  
Platelets         
Fibroblasts per microliter          
Before LD   8.2   4.4   3.3   4.2   8.1   6.1   5.72 (2.09)*  —  
After LD   0.00   0.00   0.00   0.00   0.00   0.00   0.00*  —  
Corrected CMV copies per microliter          
Before LD   88.4   631   824   1960   57.9   598   2.58 (0.59)†   380  
After LD   0.44   2.06   2.19   77.9   4.26   17.9   0.679 (0.79)†   4.77  
Log10 CMV reduction
 
2.30
 
2.49
 
2.57
 
1.40
 
1.13
 
1.52
 
1.90 (0.64)‡
 

 

The number of CMV copies is corrected for fibroblast contamination at 3 CMV copies per fibroblast.—indicates not applicable.

* Mean cell number (SD); †mean log copy number (SD); ‡mean log reduction (SD).

This system permits assessment of CMV removal by filtration using fresh PBMCs, including the relevant CD14+ population. The 2.810 log reduction in CMV with whole blood LD is consistent with previous findings using either CMV-infected T cells13  or CMV antigenemic blood with 10 to 100 times lower CMV load than used here.16  It was not possible to correlate CMV removal with residual leukocyte counts, because these were below the detection limit in all units. Although there were 2 samples in which the CMV contribution from fibroblasts was unusually high, this had no impact on the efficacy of the LD process. The incomplete CMV removal in our study cannot be attributed to filter overload, because the spiked leukocytes were derived from the donation. We have not assessed removal of granulocyte-associated CMV, but these are a minor source of latent virus.11,17 

We and others have previously reported more than 410log monocyte reduction by whole blood LD.18,19  The cause of the discrepancy between monocyte and CMV removal is not clear, but with HTLV-infected T cells and similar filters, overall T-cell reduction was also 1 log greater than HTLV Tax removal.12  It may be that monocytes activated by CMV infection are removed less well by filters than noninfected cells. Evidence for possible monocyte activation comes from recent observations reporting cytokine production by PBMCs exposed to CMV for only 18 hours, a CD14-dependent phenomenon.20  The less efficient removal of CMV by platelet than by whole blood filtration was also found with HTLV,12  although one study of filtration and centrifugal apheresis LD achieved approximately 310log CMV removal.11  We noted greater plasma contamination associated with reduced viral recovery from filters with platelet LD, raising the possibility of CMV release from leukocyte cytoplasm21  during filtration. Free CMV is not amenable to removal by LD filters,22  so release into plasma could provide a mechanism for transmission, as has been seen after poststorage LD.23  However, transient plasma viremia is seen in less than 10% of cases of primary CMV infection,24  yet transmission by plasma or derivatives is not reported, suggesting that free CMV in plasma may not be infectious. To generate an adequate CMV signal, it was necessary to superinfect components to levels 280 to 600 times greater than in CMV carriers.25  If levels of CMV reduction demonstrated here applied in CMV carriers, LD components would contain no more than 0.01 to 0.1 viral copies per microliter. Whether this residual level is sufficient to reliably prevent CMV infection in immunosuppressed recipients remains unclear. We measured genome copies, not infectious virus, and our short coculture of PBMCs with CMV-infected fibroblasts in the absence of monocyte differentiation signals would not result in PBMC expression of viral genes or infectious virus that could be titrated (J. H. Sinclair, personal communication, 2003). The balance of evidence from clinical studies still suggests that acceptable “CMV safety” can be achieved by prestorage LD. However, the incomplete CMV clearance by filtration suggests a need for greater understanding of the mechanisms and limitations of CMV removal from LD components.

Prepublished online as Blood First Edition Paper, October 2, 2003; DOI 10.1182/blood-2003-03-0762.

Funded by a grant from Pall Europe.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

The AD169 strain of human CMV and help with viral titrations was kindly provided by Dr J. H. Sinclair and Matthew Reeves, Department of Medicine, University of Cambridge. Human embryonic lung fibroblasts were a kind gift from Dr Giuseppe Gerna, Instituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy. Thanks to Janet Sutherland, Component Development Laboratory, National Blood Service (NBS) Brentwood for leukocyte enumeration.

1
Taylor-Wiedeman J, Sissons JGP, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells.
J Gen Virol
.
1991
;
72
:
2059
-2064.
2
Söderberg-Nauclér C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors.
Cell
.
1997
;
91
:
119
-126.
3
Reesink HW, Engelfriet CP, Tegetmeier GE, et al. Prevention of post-transfusion cytomegalovirus: leucoreduction or screening?
Vox Sang
.
2002
;
83
:
72
-87.
4
Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement.
Transfusion
.
2001
;
41
:
560
-569.
5
Pamphilon DH, Rider JR, Barbara JAJ, Williamson LM. Prevention of transfusion-transmitted cytomegalovirus infection.
Transfus Med
.
1999
;
9
:
115
-123.
6
Ronghe MD, Foot ABM, Cornish JM, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation.
Br J Haematol
.
2002
;
118
:
1
-4.
7
Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomaglovirus infection after receipt of leukoreduced blood products.
Blood
.
2003
;
101
:
4195
-4200.
8
Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients.
Transplantation
.
2001
;
71
:
1609
-1615.
9
Greenlee DJ, Fan H, Lawless K, Harrison CR, Gulley ML. Quantitation of CMV by real-time PCR in transfusable RBC units.
Transfusion
.
2002
;
42
:
403
-408.
10
Roback JD, Hillyer CD, Drew WL, et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors.
Transfusion
.
2001
;
41
:
1249
-1257.
11
Dumont LJ, Luka J, VandenBroeke T, Whitley P, Ambruso DR, Elfath MD. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods.
Blood
.
2001
;
97
:
3640
-3647.
12
Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV-I in blood components after leukocyte depletion.
Blood
.
2002
;
100
:
677
-681.
13
Lau W, Onizuka R, Krajden M. Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line.
J Clin Virol
.
1998
;
11
:
109
-116.
14
Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes.
J Clin Microbiol
.
1998
;
12
:
3585
-3589.
15
Nokelainen M, Nissi R, Kukkola L, Helaakoski T, Myllyharju J. Characterization of the human and mouse genes for the alpha subunit of type II prolyl 4-hydroxylase.
Eur J Biochem
.
2001
;
268
:
5300
-5309.
16
Lipson SM, Shepp DH, Match ME, Axelrod FB, Whitbread JA. Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration.
Am J Clin Pathol
.
2001
;
116
:
52
-55.
17
Taylor-Wiedeman J, Hayhurst GP, Sissons P, Sinclair J. Polymorphonuclear cells are not sites of persistence of human cytomegalovirus in healthy individuals.
J Gen Virol
.
1993
;
74
:
265
-268.
18
Pennington J, Garner S, Sutherland J, Williamson LM. Residual subset population analysis in WBC-reduced blood components using real-time PCR quantification of specific mRNA.
Transfusion
.
2001
;
41
:
1591
-1600.
19
Roback JD, Bray RA, Hillyer CD. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: implications for transfusion transmission of infections.
Transfusion
.
2000
;
40
:
500
-506.
20
Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2.
J Virol
.
2003
;
77
:
4588
-4596.
21
Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14+ cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome.
Blood
.
1999
;
93
:
394
-398.
22
Sivakumaran M, Myint S, Wood JK, Revill JA, Hutchinson RM. The efficiency of Pall BFP-4 blood filters in removing free CMV particles from stored CMV seropositive units.
Br J Haematol
.
1995
;
89
:
270
.
23
Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
Blood
.
1995
;
86
:
3598
-3603.
24
Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features.
J Infect Dis
.
1999
;
180
:
702
-707.
25
Slobedman B, Mocarski E. Quantitative analysis of latent human cytomegalovirus.
J Virol
.
1999
;
73
:
4806
-4812.

Comments

0 Comments